PedAM
Pediatric Disease Annotations & Medicines
| Disease | subependymal giant cell astrocytoma |
| Phenotype | C0041341|tuberous sclerosis |
| Sentences | 44 |
| PubMedID- 24756805 | Everolimus has been approved by the fda and the ema for the treatment of advanced renal cell carcinoma (rcc), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (tsc), pancreatic neuroendocrine tumors (pnet), in combination with exemestane in advanced hormone-receptor (hr)-positive, her2-negative breast cancer. |
| PubMedID- 21297924 | From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. |
| PubMedID- 24105488 | subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention. |
| PubMedID- 24056156 | Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors. |
| PubMedID- 23231513 | In patients with subependymal giant cell astrocytomas (segas) associated with tuberous sclerosis complex who are not candidates for surgery, single-agent everolimus has demonstrated the ability to significantly reduce sega volume with good tolerability. |
| PubMedID- 23686401 | Everolimus received subsequent approval from the fda for the treatment of advanced pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic and for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis complex in patients who require therapeutic intervention but are not amenable to surgery [22]. |
| PubMedID- 23158522 | Interpretation: these results support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 23717811 | Temsirolimus was fda-approved to treat mantle cell lymphoma (samad and younes, 2010), and everolimus was initially approved to treat renal carcinoma in 2009 (motzer et al., 2008), as well as subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis (tsc; see below) (krueger et al., 2010). |
| PubMedID- 25682485 | Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period. |
| PubMedID- 25493579 | [subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mtor inhibitors]. |
| PubMedID- 24276039 | Background: brain subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis have been reported to respond to everolimus. |
| PubMedID- 24507694 | Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. |
| PubMedID- 24708766 | The rapamycin analogs cci-779 (temsirolimus) and rad001 (everolimus) are approved for the clinical treatment of advanced renal cell carcinoma [28], progressive neuroendocrine tumors of pancreatic origin [29], subependymal giant cell astrocytoma associated with tuberous sclerosis [30], and more recently for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with the aromatase inhibitor exemestane [31]. |
| PubMedID- 23183057 | The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 22805244 | Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 26120474 | The united states food and drug administration (fda) has approved rapamycin (sirolimus) and several rapamycin derivative compounds (“rapalogs”) that inhibit mtor for the treatment of renal cancer, subependymal giant cell astrocytoma associated with tuberous sclerosis, and neuroendocrine pancreatic tumors. |
| PubMedID- 23736025 | Everolimus (afinitor, novartis pharmaceuticals, east hanover, nj, usa) is currently approved by the food and drug administration (fda) for the treatment of several malignancies including advanced renal cell carcinoma (rcc; motzer et al, 2008, 2010), progressive pancreatic neuroendocrine tumours (pnet; yao et al, 2011), subependymal giant cell astrocytomas associated with tuberous sclerosis (krueger et al, 2010) and most recently in combination with exemestane for advanced hormone receptor-positive, her-2-negative breast cancer (baselga et al, 2012). |
| PubMedID- 25557360 | Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 25143481 | Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex. |
| PubMedID- 24667738 | The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. |
| PubMedID- 24757527 | Everolimus is effective in the treatment of large angiomiolypomas (aml) in patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 20422196 | The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. |
| PubMedID- 22234227 | Hemorrhagic subependymal giant cell astrocytoma in a patient with tuberous sclerosis: case report and review of the literature. |
| PubMedID- 20887114 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. |
| PubMedID- 25456370 | Background: in the exist-1 trial, initiated on aug 10, 2009, more than 35% of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex had at least 50% reduction in sega volume after 9.6 months of treatment with everolimus. |
| PubMedID- 23138436 | The authors describe a rare case of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex that presented with intratumoral bleeding with extension to the ventricles. |
| PubMedID- 20643042 | [subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 23743818 | Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis. |
| PubMedID- 23509629 | Everolimus has been approved for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis [8–11]. |
| PubMedID- 23567018 | Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 26137524 | Everolimus has since also been fda-approved for neuroendocrine tumors of pancreatic origin (pnet), breast carcinoma, and subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis. |
| PubMedID- 25227171 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 26381530 | Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619). |
| PubMedID- 23391693 | Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations. |
| PubMedID- 23404211 | It is approved for the treatment of patients with progressive neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, and subependymal giant cell astrocytoma associated with tuberous sclerosis [12]. |
| PubMedID- 22408430 | Likewise, everolimus was approved by fda for the treatment of progressive endocrine tumours of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease and for patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (ts) (http://www.fda.gov). |
| PubMedID- 23203037 | As a result, the united states food and drug administration has approved several rapamycin (sirolimus) and rapamycin derivative compounds (“rapalogs”) for the treatment of nervous system cancers that include subependymal giant cell astrocytoma associated with tuberous sclerosis (everolimus) and neuroendocrine pancreatic tumors (everolimus) [73,99]. |
| PubMedID- 22136276 | Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 24192699 | Equally important avenues of molecular investigation might include inhibiting disease-causing pathways, such as the proposed use of rapamycin for subependymal giant cell astrocytomas in children with tuberous sclerosis;(83) upregulating affected proteins from homologous genes as in models of spinal muscular atrophy (84); or counteracting the downstream effects of a deficient protein, such as the proposed use of igf1 in children with duchenne’s dystrophy [for review, please see liew, 2012 (85)]. |
| PubMedID- 26248290 | Another report using everolimus as a treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex for approximately 3 years found the most frequent adverse events were also aphthous stomatitis and respiratory infections in children under 3 years of age, and no significant neuropsychological changes were noticed between baseline and follow-up [22]. |
| PubMedID- 23325902 | Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 23489586 | Currently, the food and drug administration (fda) has approved cci-779 for the treatment of advanced renal cell carcinoma, and rad001 for the treatment of advanced renal cell carcinoma, subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc), progressive neuroendocrine tumors of pancreatic origin, and postmenopausal women with advanced hormone-receptor-positive, her2-negative breast cancer (in combination with exemestane). |
| PubMedID- 20133820 | Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
| PubMedID- 24244540 | Everolimus has been approved for second-line therapy of patients with renal cell carcinoma after failure of treatment with sunitinib and for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis [24]–[28]. |
Page: 1